THE SEARCH FOR RATIONAL COMBINATIONS STARTS WITH THE PD-L1 PATHWAY

PD-L1 VEGF, MEK

RESEARCH THAT BUILDS ON THE FOUNDATION OF PD-L1 CHECKPOINT INHIBITION

Earlier research on the PD-L1 pathway proposed a strategy of reactivating antitumor immune responses through
PD-L1 inhibition. However, tumors may employ multiple mechanisms of immune evasion, suggesting multiple pathways may need to be targeted simultaneously to reinitiate the cancer immunity cycle. 1,2

Genentech is spearheading a rational approach to targeting multiple pathways based on identifying immune phenotypes within the framework of the cancer immunity cycle, with the goal of expanding the potential of cancer immunotherapy to more patients. 1-3

Learn more about Genentech oncology research at BioOncology.com.

By registering, you agree to allow Genentech and its agents to collect the information provided and to be contacted by Genentech and its agents in the future regarding ResearchCancerImmunotherapy.com, cancer immunotherapy research, and oncology information from Genentech BioOncology. Genentech will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Genentech and its agents. Genentech will only use your information in accordance with its Privacy Policy.